Avecho Biotechnology Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVEFF research report →
About the company
Avecho Biotechnology Limited is an Australian-based firm specializing in the development, production, and sale of various products. Central to its operations is the proprietary and patented Targeted Penetration Matrix (TPM) drug delivery system, which the company leverages across the pharmaceutical, skincare, animal health, and nutrition industries. Its product portfolio includes TPM and Vital ET, which are incorporated into drug delivery systems and cosmetic formulations.
- CEO
- Paul Gavin
- IPO
- 2018
- Employees
- 15
- HQ
- Clayton, VIC, AU
Price Chart
- Market Cap
- $13.35M
- P/E
- -25.59
- P/S
- 55.13
- P/B
- 50.52
- EV/EBITDA
- -10.84
- Div Yield
- 0.00%
- Gross Margin
- 60.70%
- Op Margin
- -485.09%
- Net Margin
- -248.73%
- ROE
- -258.19%
- ROIC
- -64.50%
- Revenue
- $1.24M · -4.38%
- Net Income
- $-4,414,887 · -41.41%
- EPS
- $0.00 · 230.00%
- Op Income
- $-6,001,941.4
- FCF YoY
- 127.78%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.20
- Avg Volume
- 193.20K
Get TickerSpark's AI analysis on AVEFF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our AVEFF coverage
Recent articles, reports, and earnings notes.
No research on AVEFF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AVEFF report →Similar companies
Peers in the same neighborhood.